JP7675009B2 - アレナウイルス感染症の治療のための化合物 - Google Patents

アレナウイルス感染症の治療のための化合物 Download PDF

Info

Publication number
JP7675009B2
JP7675009B2 JP2021525159A JP2021525159A JP7675009B2 JP 7675009 B2 JP7675009 B2 JP 7675009B2 JP 2021525159 A JP2021525159 A JP 2021525159A JP 2021525159 A JP2021525159 A JP 2021525159A JP 7675009 B2 JP7675009 B2 JP 7675009B2
Authority
JP
Japan
Prior art keywords
compound
compounds
pharma
group
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509763A (ja
JP2022509763A5 (cg-RX-API-DMAC7.html
Inventor
ブラウン エリック
レディー ガントラ ヴィディヤサーガル
ソコロヴァ ナディア
ブルーノ プレウィー マイケル
ヘンケル グレゴリー
マコーマック ケネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arisan Therapeutics Inc
Original Assignee
Arisan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics Inc filed Critical Arisan Therapeutics Inc
Publication of JP2022509763A publication Critical patent/JP2022509763A/ja
Publication of JP2022509763A5 publication Critical patent/JP2022509763A5/ja
Application granted granted Critical
Publication of JP7675009B2 publication Critical patent/JP7675009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021525159A 2018-12-06 2019-12-03 アレナウイルス感染症の治療のための化合物 Active JP7675009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
US62/776,390 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (3)

Publication Number Publication Date
JP2022509763A JP2022509763A (ja) 2022-01-24
JP2022509763A5 JP2022509763A5 (cg-RX-API-DMAC7.html) 2022-12-07
JP7675009B2 true JP7675009B2 (ja) 2025-05-12

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525159A Active JP7675009B2 (ja) 2018-12-06 2019-12-03 アレナウイルス感染症の治療のための化合物

Country Status (9)

Country Link
EP (1) EP3890731A4 (cg-RX-API-DMAC7.html)
JP (1) JP7675009B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329750B (cg-RX-API-DMAC7.html)
AR (1) AR117228A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019393784B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010909A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191001A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021005234A (cg-RX-API-DMAC7.html)
WO (1) WO2020117794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217490B (zh) * 2023-02-03 2025-09-26 中国人民解放军军事科学院军事医学研究院 一种苯并咪唑类化合物及其制备方法和应用
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
AU2024409086A1 (en) * 2023-12-20 2026-08-06 Arisan Therapeutics Inc. Crystalline forms of an imidazopyridine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
MX359989B (es) * 2012-02-17 2018-10-18 Siga Tech Inc Fármacos antivirales para el tratamiento de la infección por arenavirus.
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemistry & Industry,2009年,9 March,24-26
Glob J Pharmaceu Sci,2017年,1(4),1-11

Also Published As

Publication number Publication date
JP2022509763A (ja) 2022-01-24
MX2021005234A (es) 2021-08-11
KR20210106997A (ko) 2021-08-31
AU2019393784A1 (en) 2021-05-27
BR112021010909A2 (pt) 2021-08-24
CN113329750A (zh) 2021-08-31
WO2020117794A1 (en) 2020-06-11
EP3890731A4 (en) 2022-08-17
MX2024013042A (es) 2024-12-06
AU2019393784B2 (en) 2025-06-12
EA202191001A1 (ru) 2021-08-16
CA3118765A1 (en) 2020-06-11
AR117228A1 (es) 2021-07-21
EP3890731A1 (en) 2021-10-13
CN113329750B (zh) 2025-10-17

Similar Documents

Publication Publication Date Title
US11352328B2 (en) Heterocyclic compounds for the treatment of arenavirus
Pan et al. Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein
AU2018331172B2 (en) Influenza virus replication inhibitor and use thereof
CN112940010B (zh) 经取代的多环性吡啶酮衍生物及其前药
WO2019018185A1 (en) ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
WO2021205298A1 (en) Compounds and methods for the treatment of covid-19
US20200017514A1 (en) Adamantane derivatives for the treatment of filovirus infection
RS60350B1 (sr) Kombinovani tretman agonistom tlr7 i inhibitorom sklopa hbv kapsida
JP2022511819A (ja) ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法
BR112014007134B1 (pt) Usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso do composto para fabricação de um medicamento para tratar ou prevenir infecções flavivirais
BR112020008762A2 (pt) indol-2-carboxamidas amino-tiazol substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv)
TW202035412A (zh) 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
JP2013512246A (ja) ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
US12358897B2 (en) Compounds and method of treating COVID-19
JP6859358B2 (ja) テトラヒドロインダゾール及びその医学的使用
AU2019393784B2 (en) Compounds for the treatment of arenavirus infection
JP2018515489A (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
JP2025507472A (ja) ケトアミド系誘導体及びその製薬における使用
US12419865B2 (en) Compounds for the treatment of arenavirus infection
CA3118765C (en) Compounds for the treatment of arenavirus infection
EA044865B1 (ru) Соединения для лечения аренавирусной инфекции
WO2021262426A9 (en) Adamantane amides and thioamides for the treatment of ebolavirus infection
OA20266A (cg-RX-API-DMAC7.html)
KR20230160906A (ko) NR2B의 신규 시클로펜타[c]피롤 음성 알로스테릭 조정제
HK40079963B (en) Pyridone-containing fused ring derivative inhibitor, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250425

R150 Certificate of patent or registration of utility model

Ref document number: 7675009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150